Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum FSD Pharma Inc C.HUGE

Alternate Symbol(s):  HUGE

FSD Pharma Inc. is a Canada-based biotechnology company. The Company operates through two segments: Biotechnology and Strategic Investments. Its Biotechnology segment is focused on furthering the research and development of the Company’s two primary drug candidates consisting of Lucid-MS and Lucid-PSYCH, as well as the development of UNBUZZD. The Company’s Strategic Investments segment is... see more

CSE:HUGE - Post Discussion

FSD Pharma Inc > Insiders Loaded up
View:
Post by DavidRosenberg on Jan 11, 2022 11:56am

Insiders Loaded up

Date Issuer Insider Transaction Amount New Balance
Filed 2021-12-31 13:53
 
Tx date 2021-12-30
$HUGE
FSD Pharma Inc.
Saeed, Zeeshan
4 - Director of Issuer, 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6), 5 - Senior Officer of Issuer
Holder: Xorax Family Trust (Indirect Ownership)
Subordinate Voting Shares Class B
10 - Acquisition or disposition in the public market
$15,333
+11,111 vol
$1.38 each
385,109  
Filed 2021-12-31 13:52
 
Tx date 2021-12-30
$HUGE
FSD Pharma Inc.
Saeed, Zeeshan
4 - Director of Issuer, 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6), 5 - Senior Officer of Issuer
Holder: Xorax Family Trust (Indirect Ownership)
Subordinate Voting Shares Class B
10 - Acquisition or disposition in the public market
$76,110
+55,555 vol
$1.37 each
373,998  
Filed 2021-12-31 13:51
 
Tx date 2021-12-30
$HUGE
FSD Pharma Inc.
Saeed, Zeeshan
4 - Director of Issuer, 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6), 5 - Senior Officer of Issuer
Holder: Xorax Family Trust (Indirect Ownership)
Subordinate Voting Shares Class B
10 - Acquisition or disposition in the public market
$1,206
+900 vol
$1.34 each
318,443  
Filed 2021-12-31 13:50
 
Tx date 2021-12-30
$HUGE
FSD Pharma Inc.
Saeed, Zeeshan
4 - Director of Issuer, 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6), 5 - Senior Officer of Issuer
Direct Ownership
Subordinate Voting Shares Class B
10 - Acquisition or disposition in the public market
$50,555
+36,111 vol
$1.40 each
223,044  
Filed 2021-12-30 10:36
 
Tx date 2021-12-29
$HUGE
FSD Pharma Inc.
Carroll, Donal
4 - Director of Issuer
Direct Ownership
Subordinate Voting Shares Class B
10 - Acquisition or disposition in the public market
$9,652
+7,600 vol
$1.27 each
112,957  
Filed 2021-12-27 16:08
 
Tx date 2021-12-27
$HUGE
FSD Pharma Inc.
Carroll, Donal
4 - Director of Issuer
Direct Ownership
Subordinate Voting Shares Class B
10 - Acquisition or disposition in the public market
$9,775
+10,000 vol
$0.98 each
105,357  
Filed 2021-12-27 15:58
 
Tx date 2021-09-21
$HUGE
FSD Pharma Inc.
Kotra, Lakshmi
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Holder: ILace Therapeutics International, Inc. (Indirect Ownership)
Options
00 - Opening Balance-Initial SEDI Report
  51,473  
Filed 2021-12-27 15:57
 
Tx date 2021-11-15
$HUGE
FSD Pharma Inc.
Kotra, Lakshmi
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Options
50 - Grant of options

+165,297 vol
165,297  
Filed 2021-12-27 15:50
 
Tx date 2021-09-21
$HUGE
FSD Pharma Inc.
Kotra, Lakshmi
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
     
Filed 2021-12-27 14:10
 
Tx date 2021-12-23
$HUGE
FSD Pharma Inc.
Carroll, Donal
4 - Director of Issuer
Direct Ownership
Subordinate Voting Shares Class B
10 - Acquisition or disposition in the public market
$13,200
+10,000 vol
$1.32 each
95,357  
Filed 2021-09-24 10:58
 
Tx date 2021-09-21
$HUGE
FSD Pharma Inc.
Kotra, Lakshmi
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
     
Filed 2021-12-23 13:49
 
Tx date 2021-09-21
$HUGE
FSD Pharma Inc.
Kotra, Lakshmi
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Holder: ILace Therapeutics International, Inc. (Indirect Ownership)
Subordinate Voting Shares Class B
00 - Opening Balance-Initial SEDI Report
  865,200  
Filed 2021-12-23 13:48
 
Tx date 2021-09-21
$HUGE
FSD Pharma Inc.
Kotra, Lakshmi
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Holder: Kotra Trust (Indirect Ownership)
Subordinate Voting Shares Class B
00 - Opening Balance-Initial SEDI Report
  41,200  
Filed 2021-12-23 13:46
 
Tx date 2021-12-07
$HUGE
FSD Pharma Inc.
Kotra, Lakshmi
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Subordinate Voting Shares Class B
10 - Acquisition or disposition in the public market
$7,500
+5,000 vol
$1.50 each
298,000  
Filed 2021-12-23 13:45
 
Tx date 2021-11-05
$HUGE
FSD Pharma Inc.
Kotra, Lakshmi
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Subordinate Voting Shares Class B
10 - Acquisition or disposition in the public market
$8,004
+4,600 vol
$1.74 each
293,000  
Filed 2021-12-23 13:44
 
Tx date 2021-09-21
$HUGE
FSD Pharma Inc.
Kotra, Lakshmi
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Subordinate Voting Shares Class B
00 - Opening Balance-Initial SEDI Report
  288,400
Comment by Chefboy69 on Jan 11, 2022 11:58am
B.S cra.p...all you are doing is selling shares THATS IT the both of you...and you are bad at it...look at the pathetic VOLUME on this stock PATHETIC you both FAIL
Comment by Mil_Man54 on Jan 11, 2022 11:59am
Old and irrelevant news pumper
Comment by Chefboy69 on Jan 11, 2022 12:00pm
find a new job YOU 2 or 1 person lol
Comment by Mil_Man54 on Jan 11, 2022 12:02pm
Good idea....I could be your boss....who knows...I may already be...hmmm...
Comment by Renofund on Jan 11, 2022 3:14pm
"loading up" LOL.  Sure.  Anyway, Rosie, what price in your mind will you gloat to us?  I am curious?  As in, if this thing goes to say 10 bucks, while it may look good, it is only .05 pre-split.  $50 bucks, is about .25.  What is your price when you say "i told you so"?
Comment by DavidRosenberg on Jan 12, 2022 8:09am
"loading up" LOL.  Sure.  Anyway, Rosie, what price in your mind will you gloat to us?  I am curious?  As in, if this thing goes to say 10 bucks, while it may look good, it is only .05 pre-split.  $50 bucks, is about .25.  What is your price when you say "i told you so"? Insiders loaded up between $1.27-1.74
Comment by Walter333 on Jan 12, 2022 10:08am
"Loaded up?" That's laughable imo Mr Rosenberg as it's only a fraction of what they have already made through inflated salaries and free grants of shares and options for doing what exactly as their shareholders suffer. Insiders and BOD are the only ones who have and continue to profit. Good luck, you'll need it with this crew imo.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities